Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Adenocarcinoma: early-phase trial registry
45 of 100 indexed Prostate Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #136 of 28,707 conditions by registered trial count.
100 US clinical trials · 45 currently recruiting · #136 of 28,707 conditions by registered trial count
Prostate Adenocarcinoma: 100 US clinical trials tracked, 45 recruiting.
Prostate Adenocarcinoma is the subject of 100 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition prostate-adenocarcinoma
OPEN 45 | RECR 45% | LATE 9 | EARLY 64 | RANK #136 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Germ Cell Tumor (45% recruiting · 20 trials)
Prostate Adenocarcinoma lists 45 open slots (45% of 100 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Adenocarcinoma is recruiting above its size-band peers.
45 of 100 indexed trials (45%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Adenocarcinoma trials is spread across many organizations.
Jonsson Comprehensive Cancer Center accounts for 9 of 100 trials (9%). 50 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Adenocarcinoma enrolment sits around 78 participants.
Median target enrolment is 78 among the 100 trials that report a genuine target (sentinel values excluded). 59 of those (59%) plan for fewer than 100 participants.
-
Prostate Adenocarcinoma research is mostly interventional.
91 interventional and 9 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
100 total, page 1 of 2
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
NCT05050084
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
NCT05946213
Customized TULSA-PRO Ablation Registry
Profound Medical
NCT05001477
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group
NCT04423211
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
NCT04134260
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
Covenant Health Cancer Center
NCT06200259
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Curium US
NCT06235151
Impact of Intraoperative ICG on Functional Outc in RARP
University of California, Irvine
NCT06446648
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Case Comprehensive Cancer Center
NCT05610852
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
NCT05053152
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
University of Chicago
NCT05710380
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Stephen Freedland
NCT05832086
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Duke University
NCT06141993
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Icahn School of Medicine at Mount Sinai
NCT07285057
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Mayo Clinic
NCT06369610
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Jonsson Comprehensive Cancer Center
NCT04915508
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
NCT04175431
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Jonsson Comprehensive Cancer Center
NCT06067269
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
NCT05726292
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
National Cancer Institute (NCI)
NCT06022822
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
NCT05919329
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
Mayo Clinic
NCT06470750
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
NCT06330805
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
David Oh
NCT03821246
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
NCT03933670
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Shehzad Basaria, M.D.
NCT06957691
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
University of Virginia
NCT04465500
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Alessa Therapeutics
NCT06257693
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
NCT06798558
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT04945642
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
NCT06499870
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
Roswell Park Cancer Institute
NCT03880422
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04704505
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
NCT05806515
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Cancer Institute (NCI)
NCT05616650
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Northwestern University
NCT05852041
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
University of Miami
NCT06392295
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
NCT07025369
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
Northwestern University
NCT06813898
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
NCT06044857
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
University of Maryland, Baltimore
NCT04486755
Two-fraction HDR Monotherapy for Localized Prostate Cancer
University of California, San Francisco
NCT05665738
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
Mayo Clinic
NCT05109208
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Hoag Memorial Hospital Presbyterian
NCT06736054
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
NCT04513717
PSMA PET Imaging of Recurrent Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT03204123
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Exelixis
NCT04446117
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
NCT01786265
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT01352429
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 50 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Adenocarcinoma page
100 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Prostate Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Prostate Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Adenocarcinoma condition card totals 100 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.